This study is to observe preventive effect of (Z)-N-(2-hydroxyethyl) docos-13-enamide on hyperlipidemia and fatty liver of golden hamsters. Hyperlipidemic golden hamsters fed with high-fat diet was administered orally with (Z)-N-(2-hydroxyethyl) docos-13-enamide (10, 20 and 40 mg x kg(-1)) for 5 weeks. Levels of serum and hepatic lipid content, liver histology, hepatic MDA and SOD levels, serum ALT and AST levels were evaluated in golden hamsters. (Z)-N-(2-Hydroxyethyl) docos-13-enamide has a hypolipidemic effect, and could reduce hepatic lipid content, serum ALT and AST levels, hepatic MDA level, increase hepatic SOD activity. (Z)-N-(2-Hydroxyethyl) docos-13-enamide plays an important role in reducing serum lipid, restraining hepatic fatty deposition and protecting liver to get rid of peroxidation injury of hyperlipidemic golden hamsters. The exact lipid-lowering mechanism of (Z)-N-(2-hydroxyethyl) docos-13-enamide needs further investigation.
Alanine Transaminase ; blood ; Animals ; Aspartate Aminotransferases ; blood ; Cholesterol ; blood ; metabolism ; Cholesterol, HDL ; blood ; Cholesterol, LDL ; blood ; Cricetinae ; Erucic Acids ; chemistry ; pharmacology ; Fatty Liver ; blood ; metabolism ; pathology ; Hyperlipidemias ; blood ; metabolism ; pathology ; Hypolipidemic Agents ; chemistry ; pharmacology ; Liver ; metabolism ; pathology ; Male ; Malondialdehyde ; metabolism ; Mesocricetus ; Random Allocation ; Superoxide Dismutase ; metabolism ; Triglycerides ; blood ; metabolism